Suppr超能文献

在肾细胞癌和预后中,激活的 Akt 表达增加。

Increased activated Akt expression in renal cell carcinomas and prognosis.

机构信息

Department of Pathology, Paracelsus Medical University (PMU), Salzburg, Austria.

Department of Research (Biostatistics), Paracelsus Medical University (PMU), Salzburg, Austria.

出版信息

J Cell Mol Med. 2009 Aug;13(8B):2181-2188. doi: 10.1111/j.1582-4934.2008.00488.x.

Abstract

Renal carcinogenesis is promoted by overexpression of the activated serine/ threonine kinase Akt (p-Akt) and supposedly a concomitant reduction in phosphatase and tensin homologue deleted on chromosome 10 tumour suppressor gene (PTEN), which normally inhibits the activation of Akt. Because promising anti-cancer therapies increasingly focus on pathways involving p-Akt and PTEN, the present study evaluated the expression of p-Akt in renal cell carcinomas and compared it with prognosis. P-Akt and PTEN expression were analysed in a tissue microarray (TMA) from renal cell carcinoma (n = 386) and adjacent uninvolved renal tissue (n = 32) specimens. Increased p-Akt was found more often in the nucleus than in the cytoplasm, and PTEN was concomitantly reduced in about 50% of cases. Neither tumour grade nor stage influenced p-Akt expression, whereas the clear cell and papillary subtypes showed increased p-Akt more often than did the chromophobe or sarcomatoid types. Increased cytoplasmic and nuclear p-Akt levels were independent prognostic factors for diminishing patient survival. The present study found significantly increased nuclear but also cytoplasmic p-Akt expression in renal cell carcinoma subtypes. Increased nuclear and cytoplasmic p-Akt was an independent prognostic factor for diminishing patient survival. The considerable number of high-grade and high-stage RCC showing increased p-Akt and reduced PTEN would justify further evaluation of therapeutic concepts based on inhibitors of the PI3K/p-Akt/mTOR pathway.

摘要

肾细胞癌的发生是由激活的丝氨酸/苏氨酸激酶 Akt(p-Akt)的过度表达促进的,同时假定 10 号染色体缺失的磷酸酶和张力蛋白同系物肿瘤抑制基因(PTEN)的减少,PTEN 通常抑制 Akt 的激活。由于有前途的抗癌疗法越来越关注涉及 p-Akt 和 PTEN 的途径,本研究评估了肾细胞癌中 p-Akt 的表达,并将其与预后进行了比较。在肾细胞癌(n = 386)和相邻未受累的肾组织(n = 32)标本的组织微阵列(TMA)中分析了 p-Akt 和 PTEN 的表达。发现 p-Akt 在细胞核中的表达比在细胞质中更频繁,并且在大约 50%的情况下同时减少了 PTEN。肿瘤分级和分期均不影响 p-Akt 的表达,而透明细胞和乳头状亚型比嫌色细胞或肉瘤样类型更常显示 p-Akt 的增加。细胞质和核内 p-Akt 水平的增加是患者生存时间缩短的独立预后因素。本研究发现肾细胞癌亚型中 p-Akt 的核内和细胞质表达均显著增加。增加的核内和细胞质 p-Akt 是患者生存时间缩短的独立预后因素。相当数量的高级别和高分期的 RCC 显示出增加的 p-Akt 和减少的 PTEN,这证明了基于 PI3K/p-Akt/mTOR 途径抑制剂的治疗概念的进一步评估是合理的。

相似文献

1
Increased activated Akt expression in renal cell carcinomas and prognosis.
J Cell Mol Med. 2009 Aug;13(8B):2181-2188. doi: 10.1111/j.1582-4934.2008.00488.x.
4
Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
J Clin Pathol. 2021 Apr;74(4):216-222. doi: 10.1136/jclinpath-2020-206693. Epub 2020 May 28.
5
Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma.
Biochim Biophys Acta. 2007 Oct;1772(10):1134-42. doi: 10.1016/j.bbadis.2007.07.001. Epub 2007 Jul 12.
6
PTEN expression in renal cell carcinoma and oncocytoma and prognosis.
Pathology. 2007 Oct;39(5):482-5. doi: 10.1080/00313020701570012.
7
Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Urol Int. 2008;80(4):372-7. doi: 10.1159/000132694. Epub 2008 Jun 27.
9
Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
Clin Cancer Res. 2009 Jan 1;15(1):81-90. doi: 10.1158/1078-0432.CCR-08-0170.
10
NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma.
Urol Oncol. 2013 Aug;31(6):938-48. doi: 10.1016/j.urolonc.2011.07.006. Epub 2011 Oct 10.

引用本文的文献

1
Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma.
Nat Rev Urol. 2024 Nov;21(11):662-675. doi: 10.1038/s41585-024-00876-w. Epub 2024 May 2.
3
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Int J Mol Sci. 2021 Mar 11;22(6):2832. doi: 10.3390/ijms22062832.
4
Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma.
PeerJ. 2020 Jun 1;8:e9261. doi: 10.7717/peerj.9261. eCollection 2020.
8
miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect.
Onco Targets Ther. 2018 Mar 23;11:1643-1653. doi: 10.2147/OTT.S161586. eCollection 2018.
10
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.

本文引用的文献

2
Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma.
Biochim Biophys Acta. 2007 Oct;1772(10):1134-42. doi: 10.1016/j.bbadis.2007.07.001. Epub 2007 Jul 12.
3
Targeting the PI3K-Akt pathway in kidney cancer.
Expert Rev Anticancer Ther. 2007 Jun;7(6):863-70. doi: 10.1586/14737140.7.6.863.
5
Molecularly targeted therapy in renal cell carcinoma.
Expert Rev Anticancer Ther. 2005 Dec;5(6):1031-40. doi: 10.1586/14737140.5.6.1031.
6
Prognostic value of activated Akt expression in oral squamous cell carcinoma.
J Clin Pathol. 2005 Nov;58(11):1199-205. doi: 10.1136/jcp.2004.024786.
7
Akt activation correlates with adverse outcome in tongue cancer.
Cancer. 2005 Dec 1;104(11):2430-6. doi: 10.1002/cncr.21476.
8
PI3K/Akt/mTOR pathway as a target for cancer therapy.
Anticancer Drugs. 2005 Sep;16(8):797-803. doi: 10.1097/01.cad.0000173476.67239.3b.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验